# Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

> **NCT03452527** · PHASE2 · TERMINATED · sponsor: **Iconic Therapeutics, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Choroidal Neovascularization
- Wet Macular Degeneration

## Interventions

- **BIOLOGICAL:** ICON-1
- **BIOLOGICAL:** aflibercept

## Key facts

- **NCT ID:** NCT03452527
- **Lead sponsor:** Iconic Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-26
- **Primary completion:** 2019-04-25
- **Final completion:** 2019-04-25
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2021-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03452527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03452527, "Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03452527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*